-
公开(公告)号:US20060275897A1
公开(公告)日:2006-12-07
申请号:US11376484
申请日:2006-03-15
申请人: Gary Nabel , Bimal Chakrabarti , Wing-pui Kong , Yue Huang , Zengguang Wang , Zhi-yong Yang
发明人: Gary Nabel , Bimal Chakrabarti , Wing-pui Kong , Yue Huang , Zengguang Wang , Zhi-yong Yang
CPC分类号: A61K39/21 , A61K39/12 , A61K2039/5256 , A61K2039/53 , C07K14/005 , C12N2710/10343 , C12N2740/16122 , C12N2740/16134 , C12N2740/16222 , C12N2740/16234
摘要: In one embodiment, the invention provides a multiclade HIV plasmid DNA or viral vector vaccine including components from different clades of Env (optionally Env chimeras) and Gag-Pol-(optionally)Nef from a singlr clade. The vaccine of the invention may further include V1, V2, V3, or V4 deletions or combinations thereof. In another embodiment, the invention provides multiclade HIV envelope immunogens.
摘要翻译: 在一个实施方案中,本发明提供了多重HIV质粒DNA或病毒载体疫苗,其包括来自独立进化枝的Env(任选的Env嵌合体)和Gag-Pol-(任选地)Nef的不同进化枝的组分。 本发明的疫苗还可以包括V1,V2,V3或V4缺失或其组合。 在另一个实施方案中,本发明提供了多重HIV包膜免疫原。
-
公开(公告)号:US07666427B2
公开(公告)日:2010-02-23
申请号:US11818113
申请日:2007-06-13
申请人: Gary J. Nabel , Bimal Chakrabarti , Wing-pui Kong , Yue Huang , Zengguang Wang, legal representative , Zhi-yong Yang
发明人: Gary J. Nabel , Bimal Chakrabarti , Wing-pui Kong , Yue Huang , Zhi-yong Yang
IPC分类号: A61K39/00
CPC分类号: A61K39/21 , A61K39/12 , A61K2039/5256 , A61K2039/53 , C07K14/005 , C12N2710/10343 , C12N2740/16122 , C12N2740/16134 , C12N2740/16222 , C12N2740/16234
摘要: In one embodiment, the invention provides a multiclade HIV plasmid DNA or viral vector vaccine including components from different clades of Env (optionally Env chimeras) and Gag-Pol-(optionally)Nef from a single clade. The vaccine of the invention may further include V1, V2, V3, or V4 deletions or combinations thereof. In another embodiment, the invention provides multiclade HIV envelope immunogens.
摘要翻译: 在一个实施方案中,本发明提供了多次HIV质粒DNA或病毒载体疫苗,其包含来自单个进化枝的来自不同进化枝的Env(任选的Env嵌合体)和Gag-Pol-(任选地)Nef的组分。 本发明的疫苗还可以包括V1,V2,V3或V4缺失或其组合。 在另一个实施方案中,本发明提供了多重HIV包膜免疫原。
-
公开(公告)号:US20100111998A1
公开(公告)日:2010-05-06
申请号:US12683844
申请日:2010-01-07
申请人: Gary J. Nabel , Bimal Chakrabarti , Wing-pui Kong , Yue Huang , Zengguang Wang , Zhi-yong Yang
发明人: Gary J. Nabel , Bimal Chakrabarti , Wing-pui Kong , Yue Huang , Zengguang Wang , Zhi-yong Yang
IPC分类号: A61K39/21 , A61K31/7088
CPC分类号: A61K39/21 , A61K39/12 , A61K2039/5256 , A61K2039/53 , C07K14/005 , C12N2710/10343 , C12N2740/16122 , C12N2740/16134 , C12N2740/16222 , C12N2740/16234
摘要: In one embodiment, the invention provides a multiclade HIV plasmid DNA or viral vector vaccine including components from different clades of Env (optionally Env chimeras) and Gag-Pol-(optionally)Nef from a single Glade. The vaccine of the invention may further include V1, V2, V3, or V4 deletions or combinations thereof. In another embodiment, the invention provides multiclade HIV envelope immunogens.
摘要翻译: 在一个实施方案中,本发明提供了多次HIV质粒DNA或病毒载体疫苗,其包括来自单一Glade的来自不同进化枝的Env(任选的Env嵌合体)和Gag-Pol-(任选地)Nef的组分。 本发明的疫苗还可以包括V1,V2,V3或V4缺失或其组合。 在另一个实施方案中,本发明提供了多重HIV包膜免疫原。
-
公开(公告)号:US20080286306A1
公开(公告)日:2008-11-20
申请号:US11818113
申请日:2007-06-13
申请人: Gary J. Nabel , Bimal Chakrabarti , Wing-pui Kong , Yue Huang , Zhi-yong Yang , Zengguang Wang
发明人: Gary J. Nabel , Bimal Chakrabarti , Wing-pui Kong , Yue Huang , Zhi-yong Yang , Zengguang Wang
CPC分类号: A61K39/21 , A61K39/12 , A61K2039/5256 , A61K2039/53 , C07K14/005 , C12N2710/10343 , C12N2740/16122 , C12N2740/16134 , C12N2740/16222 , C12N2740/16234
摘要: In one embodiment, the invention provides a multiclade HIV plasmid DNA or viral vector vaccine including components from different clades of Env (optionally Env chimeras) and Gag-Pol-(optionally)Nef from a single clade. The vaccine of the invention may further include V1, V2, V3, or V4 deletions or combinations thereof. In another embodiment, the invention provides multiclade HIV envelope immunogens.
摘要翻译: 在一个实施方案中,本发明提供了多次HIV质粒DNA或病毒载体疫苗,其包含来自单个进化枝的来自不同进化枝的Env(任选的Env嵌合体)和Gag-Pol-(任选地)Nef的组分。 本发明的疫苗还可以包括V1,V2,V3或V4缺失或其组合。 在另一个实施方案中,本发明提供了多重HIV包膜免疫原。
-
公开(公告)号:US20090208531A1
公开(公告)日:2009-08-20
申请号:US12279332
申请日:2007-02-16
申请人: Gary J. Nabel , Wing-pui Kong , Zhi-yong Yang
发明人: Gary J. Nabel , Wing-pui Kong , Zhi-yong Yang
IPC分类号: A61K39/145 , C12N15/11 , A61K31/7088 , C12N15/00
CPC分类号: C07K14/005 , A61K38/00 , A61K39/12 , A61K39/145 , A61K2039/53 , C07K2319/21 , C07K2319/70 , C12N2710/10343 , C12N2740/16043 , C12N2740/16134 , C12N2760/16122 , C12N2760/16134
摘要: These vaccines target H5N1, H1, H3 and other subtypes of influenza and are designed to elicit neutralizing antibodies, as well as cellular immunity. The DNA vaccines express hemagglutinin (HA) or nucleoprotein (NP) proteins from influenza which are codon optimized and/or contain modifications to protease cleavage sites of HA which affect the normal function of the protein. Adenoviral constructs expressing the same inserts have been engineered for prime boost strategies. Protein-based vaccines based on protein production from insect or mammalian cells using foldon trimerization stabilization domains with or without cleavage sites to assist in purification of such proteins have been developed. Another embodiment of this invention is the work with HA pseudotyped lentiviral vectors which would be used to screen for neutralizing antibodies in patients and to screen for diagnostic and therapeutic antivirals such as monoclonal antibodies.
摘要翻译: 这些疫苗靶向H5N1,H1,H3和其他亚型亚型,旨在引发中和抗体以及细胞免疫。 DNA疫苗表达来自流感的血凝素(HA)或核蛋白(NP)蛋白,其密码子优化和/或含有影响蛋白质正常功能的HA蛋白酶切割位点的修饰。 表达相同插入片段的腺病毒构建体已被设计用于主要的增强策略。 已经开发了基于使用具有或不具有切割位点的折叠三聚稳定结构域的昆虫或哺乳动物细胞的基于蛋白质产生的蛋白质疫苗,以有助于这种蛋白质的纯化。 本发明的另一个实施方案是具有HA假型慢病毒载体的工作,其将用于筛选患者中的中和抗体并筛选诊断和治疗性抗病毒剂,例如单克隆抗体。
-
公开(公告)号:US20100074916A1
公开(公告)日:2010-03-25
申请号:US12443964
申请日:2007-10-10
申请人: Gary J. Nabel , Zhi-yong Yang , Chih-jen Wei , Wing-pui Kong , Lan Wu
发明人: Gary J. Nabel , Zhi-yong Yang , Chih-jen Wei , Wing-pui Kong , Lan Wu
IPC分类号: A61K39/145 , C07K14/005 , C07K16/00 , C07H21/04 , C07H21/02 , C12P21/00
CPC分类号: A61K39/145 , A61K39/12 , A61K2039/53 , C07K14/005 , C12N2710/10343 , C12N2740/15043 , C12N2760/16122 , C12N2760/16134 , C12N2810/6072
摘要: H5 hemagglutinin (HA) polypeptides are provided that are adapted to humans through mutations that change receptor specificity in the H1 serotype, and related polynucleotides, methods, compositions, and vaccines.
摘要翻译: 提供H5血凝素(HA)多肽,其通过改变H1血清型中的受体特异性的突变以及相关的多核苷酸,方法,组合物和疫苗适应人类。
-
-
-
-
-